GeneWerk GmbH, a Heidelberg, Germany-based cell and gene therapy testing laboratory focused on providing preclinical and clinical trial patient sample analysis services, received a majority investment from Ampersand Capital Partners.
The amount of the deal was not disclosed.
The company intends to use the funds to expand its capabilities to meet the demand for cell and gene therapy testing services.
Led by Annette Deichmann, Ph.D., and Manfred Schmidt, Ph.D., GeneWerk provides cell and gene therapy sponsors with patient testing services in compliance with guidance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is a provider of vector integration site analysis (ISA) services, a method that was developed by GeneWerk’s founders and that the FDA and EMA recommend performing after the administration of both integrating and non-integrating cell and gene therapies. The company’s test menu also includes vector persistence testing, gene edited off-target analysis, vector copy number (VCN), vector quality control, immune repertoire analysis, and dedicated bioinformatics studies. With a focus on vector safety, characterization, and functionality analysis, the company’s 30 employees work in compliance with GCP and in line with GLP standards in a BSL-2 classified state-of-the-art genomics and bioinformatics laboratory in Heidelberg, Germany.